retatrutide clinical trials safety efficacy Retatrutide: A Promising Option for Non-Diabetic Weight Loss in Triple hormone receptor agonist retatrutide

However, this same mechanism may contribute to gastrointestinal side effects, which are among the most commonly reported adverse reactions with GLP-1 therapy

Inflammatory bowel syndrome Stomach ulcers Bone fractures Injured ligaments, nerves, and muscles Tendinopathies (tendon injuries) like tennis or golf elbow, trigger fingers, or Achilles tendinitis Ulcerative colitis (short bowel syndrome, anastomosis, and fistula) Perforated cecum (part of the large intestine) Post-surgery recovery Spinal cord injuries Arrhythmia (irregular heartbeat) Periodontitis (gum damage) The outcomes for rats may differ from those for humans

Prevent subsequent cell death in the case of adult, neonatal, and pediatric brain injury

A licensed professional will review your profile to determine if a GLP-1 or dual-agonist medication is right for you

For example, estrogen signaling has been shown to enhance the anorexigenic effects of GLP-1 RAs by modulating central pathways involved in food reward, which could account for the more pronounced weight loss observed in premenopausal women [49, 50]

Jackson AA, Persaud C, Hall M, Smith S, Evans N, Rutter N: Urinary excretion of 5-L-oxoproline (pyroglutamic acid) during early life in term and preterm infants